Purchased was Meihua International Medical Technologies’s largest product and service line in fiscal 2025, bringing in $34.51M of $61.79M (56%).
| Product and Service | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Resales Of Sourced Disposable Medical Devices From Third Party Manufacturers | — | — | — | |
| Purchased | $48.90M | $49.30M | $34.51M | |
| Produced | $48.20M | $47.61M | $27.28M | |
| Class I | — | — | — | |
| Others | — | — | — | |
| Class Iii | — | — | — | |
| Total | $97.10M | $96.91M | $61.79M |
Meihua International Medical Technologies brought in $61.79M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 36.2% from $96.91M in fiscal 2024. Purchased was the largest at $34.51M (55.9%), ahead of Produced at $27.28M (44.1%).
Compared with fiscal 2024, Purchased fell 30.0% to $34.51M and Produced fell 42.7% to $27.28M. From fiscal 2023 to 2025, combined revenue from these lines fell from $97.10M to $61.79M, a compound annual decline of 20.2%. Purchased's share of the total rose from 50.4% to 55.9%.
Third Party Sales was Meihua International Medical Technologies’s largest revenue line in fiscal 2025, bringing in $60.96M of $61.79M (99%).
| Related and Nonrelated Parties | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Third Party Sales | $103.32M | $96.68M | $96.14M | $60.96M | |
| Related Party | $29.20K | $416.44K | $768.55K | $831.33K | |
| Yangzhou Meihua Import & Export Co., Ltd | $18.78K | — | — | — | |
| Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd | $10.42K | — | — | — | |
| Total | $103.38M | $97.10M | $96.91M | $61.79M |
Meihua International Medical Technologies brought in $61.79M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 36.2% from $96.91M in fiscal 2024. Third Party Sales was the largest at $60.96M (98.7%), ahead of Related Party at $831.33K (1.3%).
Meihua International Medical Technologies stopped reporting Yangzhou Meihua Import & Export Co., Ltd ($18.78K in fiscal 2022) and Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd ($10.42K in fiscal 2022) as separate revenue lines.
Distributors was Meihua International Medical Technologies’s largest revenue line in fiscal 2021, bringing in $94.54M of $104.04M (91%).
| Customer | FY 2021 |
|---|---|
| Distributors | $94.54M |
| Direct Sales | $9.50M |
| Total | $104.04M |
Meihua International Medical Technologies brought in $104.04M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Distributors was the largest at $94.54M (90.9%), ahead of Direct Sales at $9.50M (9.1%).
Meihua International Medical Technologies (MHUAF) reports its revenue by product and service, by related and nonrelated parties and by customer. In fiscal 2025, Purchased was its largest product and service line, bringing in $34.51M (55.9% of the total), followed by Produced at $27.28M (44.1%).
Purchased was Meihua International Medical Technologies' largest product and service line in fiscal 2025, bringing in $34.51M, or 55.9% of the $61.79M total across its two product and service lines.
Third Party Sales was Meihua International Medical Technologies' largest revenue line in fiscal 2025, bringing in $60.96M, or 98.7% of the $61.79M total across its two revenue lines.
Every figure comes from Meihua International Medical Technologies' annual financial filings, as reported. Each line keeps the name Meihua International Medical Technologies gives it, and years follow its fiscal calendar.
Meihua International Medical Technologies' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.